Stephan Forchhammer, Valentin Aebischer, Daniela Lenders, Christian M Seitz, Christopher Schroeder, Alexandra Liebmann, Michael Abele, Hannah Wild, Ewa Bien, Malgorzata Krawczyk, Dominik T Schneider, Ines B Brecht, Lukas Flatz, Matthias Hahn
Pediatric melanomas are rare tumors that have clinical and histological differences from adult melanomas. In adult melanoma, the immunohistochemical marker PRAME is increasingly employed as a diagnostic adjunct. PRAME is also under investigation as a target structure for next-generation immunotherapies including T-cell engagers. Little is known about the characteristics of PRAME expression in pediatric melanoma. In this retrospective study, samples from 25 pediatric melanomas were compared with control groups of melanomas in young adults (18-30 years; n = 32), adult melanoma (>30 years, n = 30), and benign melanocytic nevi in children (0-18 years; n = 30) with regard to the immunohistochemical expression of PRAME (diffuse PRAME expression >75%/absolute expression)...
March 20, 2024: Pigment Cell & Melanoma Research